The gut microbiome and intestinal failure-associated liver disease  

作　　者：Lu Jiang Juan Xu Si-Yang Cheng Ying Wang Wei Cai 

机构地区：[1]Division of Pediatric Gastroenterology and Nutrition,Xinhua Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200092,China [2]Shanghai Institute for Pediatric Research,Shanghai 200092,China [3]Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition,Shanghai 200092,China [4]Department of Pediatric Surgery,Xinhua Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200092,China

出　　处：《Hepatobiliary & Pancreatic Diseases International》2023年第5期452-457,共6页国际肝胆胰疾病杂志（英文版）

基　　金：This study was supported by grants from the National Natural Science Foundation of China(82100950);Shanghai Natural Sci-ence Foundation(23ZR1452600).

摘　　要：Intestinal failure-associated liver disease(IFALD)is a common hepatobiliary complication resulting from long-term parenteral nutrition(PN)in patients with intestinal failure.The spectrum of IFALD ranges from cholestasis,steatosis,portal fibrosis,to cirrhosis.Development of IFALD is a multifactorial process,in which gut dysbiosis plays a critical role in its initiation and progression in conjunction with increased intestinal permeability,activation of hepatic immune responses,and administration of lipid emulsion.Gut microbiota manipulation including pre/probiotics,fecal microbiota transplantation,and antibiotics has been studied in IFALD with varying success.In this review,we summarize current knowledge on the taxonomic and functional changes of gut microbiota in preclinical and clinical studies of IFALD.We also review the function of microbial metabolites and associated signalings in the context of IFALD.By providing microbiota-targeted interventions aiming to optimize PN-induced liver injury,our review provides perspectives for future basic and translational investigations in the field.

关 键 词：Parenteral nutrition MICROBIOTA Bile acid Short-chain fatty acid PREBIOTICS PROBIOTICS 

分 类 号：R575[医药卫生—消化系统]